Delivery Order SPE2DB22D1106-SPE2DB25FEPJ0
- Not listed
- The Defense Logistics Agency awarded a $4,211.79 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors. This firm fixed price, non-set-aside contract is scheduled for completion by August 1, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's extensive pharmaceutical supply relationship with the federal...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors in 0.5 mL unit doses, with a ceiling value of $1,599.58. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order valued at $20,289.80 to AmerisourceBergen Drug Corp for the supply of Imitrex 6 mg/0.5 ml pen injectors on April 21, 2025, with an ultimate completion date of April 22, 2025. This firm fixed-price, non-set-aside contract represents a single delivery order executed under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's headquarters location in...
- The Department of Defense awarded a delivery order valued at $2,278.68 to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors in 0.5 mL formulations. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and is funded through the Defense Logistics...
- The Defense Logistics Agency awarded a $5,405.03 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Imitrex 4 mg/0.5 mL pen injections (0.5 mL units). The contract represents a firm fixed price delivery order with an ultimate completion date of April 25, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $13,635.81 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 11, 2025, for the supply of Imitrex 6 mg/0.5 ml pen injectors. The contract, which carries an ultimate completion date of July 14, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen will perform this work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,020.74 by the Defense Logistics Agency's Medical Supply Chain on August 15, 2025, for the supply of Imitrex 6 mg/0.5 ml pen injectors. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 18, 2025. The delivery order represents a child contract under...
- The U.S. Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injections with a ceiling value of $2,587.82. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open procurement. The order is scheduled for completion by July 16, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp was awarded a $4,896.10 delivery order by the Defense Logistics Agency's Medical Supply Chain on July 28, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors. This firm fixed-price contract, designated as a non-set-aside award, is scheduled for completion by July 29, 2025, with performance to be executed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency has awarded a $2,288.07 delivery order to AmerisourceBergen Drug Corp for IMITREX 4 mg/0.5 mL pen injectors, with an ultimate completion date of May 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, and the company's corporate office is designated as both the...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEPJ0Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,995.78 on May 20, 2025, for the supply of Imitrex 6 mg/0.5 mL pen injectors in 0.5 mL quantities. This is a firm fixed price, non-set-aside competitive award with an ultimate completion date of May 21, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order represents a continuation of AmerisourceBergen's pharmaceutical supply relationship with DLA, one of the Department of Defense's primary medical procurement mechanisms. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and healthcare solutions provider, AmerisourceBergen serves critical federal medical procurement needs across the military and veteran healthcare systems, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. The firm's demonstrated capability to fulfill federal requirements through open competition reflects its significance as a prime vendor for DLA's medical supply chain operations supporting Defense Health Agency customers and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.0k | 5/20/25 |